INVESTIGATING THE ROLE OF THE TRANSCRIPTIONAL COREGULATOR SRC-2 IN CASTRATION RESISTANT PROSTATE CANCER
INVESTIGATING THE ROLE OF THE TRANSCRIPTIONAL COREGULATOR SRC-2 IN CASTRATION RESISTANT PROSTATE CANCER
批准号:
9763341
负责人:
Subhamoy Dasgupta
金额:
$20.67万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2021-03-31
关键词:
AblationAcetylationAconitate HydrataseAndrogen ReceptorAutomobile DrivingBiochemicalBioenergeticsBiological AssayCancer PatientCaringChIP-seqChromatinClinicalClinical TrialsData SetDeacetylaseDevelopmentDiseaseDisease-Free SurvivalDistantDropsDrug resistanceEarly DiagnosisEnzymesEventGRIP1 geneGeneticGenetic TranscriptionGlutamineGoalsGrowthHyperactive behaviorImmunoprecipitationImpairmentIn VitroIsotopesK22 AwardLeadLinkLipidsMalignant NeoplasmsMalignant neoplasm of prostateMass Spectrum AnalysisMetabolicMetabolic PathwayMetabolismMitochondriaModelingMolecularNCOA2 geneNeoplasm MetastasisNutrientOncogenicOperative Surgical ProceduresOrganPathway interactionsPatientsPharmacologyPhenotypePlayPrognostic MarkerProstatic NeoplasmsProteinsRadiation therapyRecurrenceResistance developmentRoleSignal PathwaySignal TransductionSourceSteroid ReceptorsSurvival RateTherapeuticTracerTranslatingWorkalpha ketoglutarateandrogen deprivation therapybasebench to bedsidebonecancer typecarboxylationcastration resistant prostate cancerchemotherapyclinically significantfatty acid biosynthesisgenetic signaturegenome-widein vivoin vivo Modelinhibitor/antagonistinsightlipid biosynthesismacromoleculemenmouse modelnovelnovel therapeuticsoverexpressionprognostic toolprostate cancer metastasisprostate cancer progressionresponsetargeted agenttherapeutic biomarkertherapy resistanttranscription factortumortumor metabolismtumor progression
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Therapeutic management of metastatic castration-resistant prostate cancer (mCRPC) remains a major clinical
challenge. Localized or organ-confined prostate cancer can be cured by surgery, or a combination of androgen
deprivation therapy (ADT), radiotherapy and/or chemotherapy. However, tumor recurrence occurs in some
men due to the development of ADT-resistant clones which greatly contributes to the lethality of prostate
cancer. Aggressive mCRPC frequently metastasizes to distant organs such as bone. As a result treatment
becomes challenging and survival rate drops. Hence, there is an urgent need to develop new therapies to cure
advanced prostate cancer. Development of aggressive disease is favored by activation of several `escape
pathways' among which AR- coactivators such as steroid receptor coactivator-2 (SRC-2/NCOA2) plays a
critical role promoting the survival and rapid metastasis of CRPC. SRC-2 promotes a “metabolic switch” in
advanced tumors that predispose them to be dependent on `glutamine' to generate energy and
macromolecules required for survival and metastatic growth. Ablation of SRC-2 suppresses prostate tumor
survival and metastasis in vivo, indicating this may be a viable approach to treat advanced patients. So our
objectives in this proposal are (1) to investigate the mechanisms that promote increased glutamine metabolism
in tumors, (2) identify the upstream signaling events that stimulate SRC-2 transcriptional responses to regulate
this metabolic reprogramming, and (3) examine the therapeutic benefits of targeting this `metabolic switch' to
block cancer progression and metastasis. During the K22 award I expect to identify the molecular links
between cellular metabolism and oncogenic events in mCRPC, and examine the potential benefits of targeting
this pathway to selectively impair prostate cancer metastasis. The study will make novel insights depicting the
altered metabolic pathways and underlying mechanisms promoting the emergence of CRPC, which may lead
to the discovery of potential prognostic tools for early detection of clinically significant disease.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1038/s41598-021-82945-3
发表时间:
2021-02-09
期刊:
Scientific reports
影响因子:
4.6
作者:
[Nikolai BC, Jain P, Cardenas DL, York B, Feng Q, McKenna NJ, Dasgupta S, Lonard DM, O'Malley BW]
通讯作者:
O'Malley BW
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer
-
批准号:10818087
-
项目类别:
-
资助金额:$5.26万
-
财政年份:2023
-
负责人:Subhamoy Dasgupta
-
依托单位:
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer
-
批准号:10590678
-
项目类别:
-
资助金额:$34.99万
-
财政年份:2021
-
负责人:Subhamoy Dasgupta
-
依托单位:
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer
-
批准号:10376802
-
项目类别:
-
资助金额:$35.45万
-
财政年份:2021
-
负责人:Subhamoy Dasgupta
-
依托单位:
Mechanisms of metabolic stress-induced transcriptional regulation in prostate cancer
-
批准号:10209389
-
项目类别:
-
资助金额:$36.47万
-
财政年份:2021
-
负责人:Subhamoy Dasgupta
-
依托单位:
Decoding the nuclear metabolic processes regulating gene transcription
-
批准号:10001134
-
项目类别:
-
资助金额:$252.3万
-
财政年份:2020
-
负责人:Subhamoy Dasgupta
-
依托单位:
海外基金